This chapter discusses how model-based design of experiments (MBDoE) techniques may be instrumental to the model development and identification effort in pharmacokinetics and pharmacodynamics. After introducing the formal MBDoE framework, two case studies will be discussed to show how the methodology can be implemented, and to illustrate the benefits in terms of parametric estimation. The first case study considers a model describing in vitro bacterial growth and killing, whereas the second one focuses on a physiological description of the von Willebrand disease. The effectiveness of the MBDoE approach will be demonstrated through a comparison with standard pharmacological experiments and clinical tests
Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments D i
A novel and systematic model-based design of experiments (MBDoE) strategy is proposed to develop rob...
In this paper, the philosophy of a research in pharmacology field, driven by an engineering approach...
The use of pharmacokinetic (PK) and pharmacodynamic (PD) models is a common and widespread practice ...
General attrition rates in drug development pipeline have been recognized as a necessity to shift ge...
1 We discuss design issues for pharmacokinetic and pharmacodynamic (PK/PD) models and provide closed...
Tuberculosis, the leading cause of death by a single infection disease caused by bacteria, requires ...
Methods of optimal experimental design potentially are very useful tool in research practice. There ...
Providing more than just a comprehensive history, critical vocabulary, insightful compilation of mot...
Pharmacokinetic studies have turned into the focus of pharmaceutical companies, after studies manife...
Physiological models are mathematical models characterized by a physiologically consistent mathemati...
The simulation of therapeutic models and clinical trial simulation have recently attracted attention...
Pharmacokinetics is the study of the fate of xenobiotics in a living organism. Physiologically based...
The goal of this manuscript is to introduce a framework for consideration of designs for population ...
The cost of releasing a new drug on the market has increased rapidly in the last decade. The reasons...
Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments D i
A novel and systematic model-based design of experiments (MBDoE) strategy is proposed to develop rob...
In this paper, the philosophy of a research in pharmacology field, driven by an engineering approach...
The use of pharmacokinetic (PK) and pharmacodynamic (PD) models is a common and widespread practice ...
General attrition rates in drug development pipeline have been recognized as a necessity to shift ge...
1 We discuss design issues for pharmacokinetic and pharmacodynamic (PK/PD) models and provide closed...
Tuberculosis, the leading cause of death by a single infection disease caused by bacteria, requires ...
Methods of optimal experimental design potentially are very useful tool in research practice. There ...
Providing more than just a comprehensive history, critical vocabulary, insightful compilation of mot...
Pharmacokinetic studies have turned into the focus of pharmaceutical companies, after studies manife...
Physiological models are mathematical models characterized by a physiologically consistent mathemati...
The simulation of therapeutic models and clinical trial simulation have recently attracted attention...
Pharmacokinetics is the study of the fate of xenobiotics in a living organism. Physiologically based...
The goal of this manuscript is to introduce a framework for consideration of designs for population ...
The cost of releasing a new drug on the market has increased rapidly in the last decade. The reasons...
Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments D i
A novel and systematic model-based design of experiments (MBDoE) strategy is proposed to develop rob...
In this paper, the philosophy of a research in pharmacology field, driven by an engineering approach...